Related Experiment Videos
Treating tuberculous lymphadenitis--ifs and buts
Sumita Mukherjee1, Supriyo Sarkar
1Department of TB and Respiratory Diseases, Calcutta National Medical College & Hospital, Calcutta.
Journal of the Indian Medical Association
|July 5, 2003
Summary
Tuberculous (TB) lymphadenitis diagnosis and treatment are complex, especially with rising atypical mycobacteria and drug resistance. Effective management requires specialized care and monitoring for TB lymph node infections.
Area of Science:
- Infectious Diseases
- Microbiology
- Immunology
Background:
- Tuberculous (TB) lymphadenitis presents diagnostic and therapeutic challenges due to complex aetiopathologies.
- Increased incidence of atypical mycobacteria and multi-drug resistance (MDR) complicate TB lymphadenitis management.
- Improved life expectancy in immunocompromised patients contributes to a rise in atypical mycobacterial infections.
Purpose of the Study:
- To highlight the complexities in diagnosing and treating tuberculous lymphadenitis.
- To discuss the impact of atypical mycobacteria and drug resistance on TB lymphadenitis.
- To suggest effective antimicrobial agents for atypical mycobacteria-induced lymphadenitis.
Main Methods:
- Literature review on TB lymphadenitis aetiopathologies and treatment outcomes.
- Analysis of diagnostic challenges including repeated biopsies.
- Evaluation of treatment monitoring complexities in TB lymph nodes.
Main Results:
- Diagnosis of TB lymphadenitis often requires multiple biopsies.
- Atypical mycobacteria and MDR are increasing challenges in TB lymphadenitis.
- Clarithromycin, ethambutol, rifabutin, and amikacin show efficacy against atypical mycobacteria-induced lymphadenitis.
Conclusions:
- TB lymphadenitis demands specialist intervention due to its multifaceted nature.
- The rise of atypical mycobacteria and drug resistance necessitates tailored treatment strategies.
- Careful selection of antibiotics is crucial for managing drug-resistant and atypical mycobacterial lymphadenitis.